Ramorelix

Summary

Ramorelix is an investigational gonadotropin‑releasing hormone (GnRH) antagonist studied in rats for its ability to suppress ovarian hormone production and to affect hormone‑dependent mammary tumours. The compound is delivered in biodegradable slow‑release microparticles or implants and is being explored as a research tool for cancer prevention and treatment, not as an approved therapy.

Mechanism of Action

As a GnRH antagonist, ramorelix binds competitively to pituitary GnRH receptors, blocking the normal pulsatile GnRH signal. This prevents the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), leading to rapid suppression of ovarian (and testicular) steroidogenesis. The resulting drop in circulating oestrogens is thought to inhibit growth of hormone‑dependent tumours, and the peptide may also exert direct antiproliferative effects on tumour cells, as suggested by animal experiments.

What the Research Shows

A 1993 rat study compared ramorelix microparticles (3.6 mg peptide) with the GnRH agonist buserelin in a dimethyl‑benz[a]anthracene (DMBA) model of mammary carcinoma. In a curative setting, a single ramorelix injection halted tumour progression for about 14 days, whereas buserelin caused rapid tumour regression and prevented growth for up to 120 days. In a preventive protocol, ramorelix microparticles given weekly (1.8 mg peptide) blocked tumour emergence, but tumour growth resumed six weeks after the final dose. The investigators reported a clear correlation between peptide release rates and tumour inhibition, and noted that the formulations were well tolerated with no observable tissue reaction in the animals.

Reported Benefits

In the animal model, ramorelix demonstrated the ability to prevent the onset of hormone‑dependent mammary tumours when administered in a frequent, low‑dose schedule, and it could temporarily suspend tumour progression in established cancers. The rapid onset of gonadal suppression, due to its antagonist profile, may offer a pharmacokinetic advantage for research applications that require immediate hormone blockade.

Limitations of the Evidence

The antitumour effect of ramorelix was short‑lived, lasting only about two weeks after a single dose, and was less robust than the GnRH agonist buserelin in curative experiments. Evidence is confined to a single rodent study of chemically induced mammary cancer; no data exist for other tumour types, other species, or humans. Consequently, efficacy, optimal dosing, and long‑term safety remain uncharacterised.

Safety Considerations

The cited rat study reported no local tissue reaction or overt side‑effects from ramorelix microparticles or implants, indicating good tolerability in that species. However, safety in humans has not been evaluated, and potential endocrine disturbances, injection‑site reactions, or off‑target effects cannot be ruled out without clinical data.

How It Is Administered

Ramorelix is investigated as a biodegradable polymer‑based formulation (microparticles or implants) intended for subcutaneous or intravenous administration. The delivery system provides a controlled release of the peptide over days to weeks, with release kinetics influencing the duration of gonadal suppression.

Routes of Administration

Goals & Uses

• Assisted reproduction / controlled ovarian stimulationReproductive MedicineLow
• Benign prostatic hyperplasia (BPH)UrologyLow
• Prostate cancer treatmentOncologyLow
• EndometriosisGynecologyLow

Contraindications

• Known hypersensitivity to GnRH analogsAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• Injection site reactionsLocalCommon
• Histamine release / allergic reactionImmunologicUncommon
• Hypogonadism symptomsEndocrineCommon
• Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

• QT-prolonging agentsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with cardiovascular diseaseComorbidityRelative

Regulatory Status

• European UnionUnapprovedNever received EMA approval; clinical trials conducted in Europe in the 1990s but not progressed.
• United StatesUnapprovedNever submitted for or received FDA approval; development discontinued.
• United KingdomUnapprovedNo regulatory approval in the UK.

Ramorelix was never approved by any major regulatory authority. Clinical development was halted; it remains a research-stage compound with no approved indications.

Evidence & Sources

• Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations
  Journal ArticleLowStoeckemann K, Sandow J1993-01-01T00:00:00.000000Z

Frequently Asked Questions